Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study.

Karina Dahl Steffensen; Marianne Waldstrom; Niels Pallisgård; Bente Lund; Kjell Bergfeldt; Jessica Wihl; Nina Keldsen; Christian Marth; Ignace B. Vergote; Anders Kristian Moeller Jakobsen

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study.

Karina Dahl Steffensen, Marianne Waldstrom, Niels Pallisgård, Bente Lund, Kjell Bergfeldt, Jessica Wihl, Nina Keldsen, Christian Marth, Ignace B. Vergote, Anders Kristian Moeller Jakobsen

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Journal	Journal of Clinical Oncology
Volume	30
Issue number	15
ISSN	0732-183X
Publication status	Published - 20 May 2012
Externally published	Yes
Event	American Society of Clinical Oncology - Chicago, United States Duration: 1 Jun 2012 → 5 Jun 2012 Conference number: 48

Conference

Conference	American Society of Clinical Oncology
Number	48
Country/Territory	United States
City	Chicago
Period	01/06/2012 → 05/06/2012

Bibliographical note

PT: J; CT: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO); CY: JUN 01-06, 2012; CL: Chicago, IL; SP: Amer Soc Clin Oncol (ASCO); NR: 0; TC: 0; J9: J CLIN ONCOL; SU: S; PG: 1; GA: 131QQ; UT: WOS:000318009803644

Keywords

Oncology

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Steffensen, K. D., Waldstrom, M., Pallisgård, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. B., & Jakobsen, A. K. M. (2012). Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study. Journal of Clinical Oncology, 30(15).

@article{c4bd528fcc324044af7b1fc345c57309,

title = "Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study.",

keywords = "Oncology",

author = "Steffensen, {Karina Dahl} and Marianne Waldstrom and Niels Pallisg{\aa}rd and Bente Lund and Kjell Bergfeldt and Jessica Wihl and Nina Keldsen and Christian Marth and Vergote, {Ignace B.} and Jakobsen, {Anders Kristian Moeller}",

note = "PT: J; CT: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO); CY: JUN 01-06, 2012; CL: Chicago, IL; SP: Amer Soc Clin Oncol (ASCO); NR: 0; TC: 0; J9: J CLIN ONCOL; SU: S; PG: 1; GA: 131QQ; UT: WOS:000318009803644; American Society of Clinical Oncology ; Conference date: 01-06-2012 Through 05-06-2012",

year = "2012",

month = may,

day = "20",

language = "English",

volume = "30",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

}

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study. / Steffensen, Karina Dahl; Waldstrom, Marianne; Pallisgård, Niels et al.
In: Journal of Clinical Oncology, Vol. 30, No. 15, 20.05.2012.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study.

AU - Steffensen, Karina Dahl

AU - Waldstrom, Marianne

AU - Pallisgård, Niels

AU - Lund, Bente

AU - Bergfeldt, Kjell

AU - Wihl, Jessica

AU - Keldsen, Nina

AU - Marth, Christian

AU - Vergote, Ignace B.

AU - Jakobsen, Anders Kristian Moeller

N1 - Conference code: 48

PY - 2012/5/20

Y1 - 2012/5/20

KW - Oncology

M3 - Conference abstract in journal

SN - 0732-183X

VL - 30

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

T2 - American Society of Clinical Oncology

Y2 - 1 June 2012 through 5 June 2012

ER -